STOCK TITAN

Vera Therapeutics, Inc. - VERA STOCK NEWS

Welcome to our dedicated page for Vera Therapeutics news (Ticker: VERA), a resource for investors and traders seeking the latest updates and insights on Vera Therapeutics stock.

Vera Therapeutics, Inc. (Nasdaq: VERA) is a late clinical-stage biotechnology company committed to developing and commercializing pioneering treatments for patients with serious immunological diseases. The company's primary product candidate, atacicept, is a fusion protein designed for subcutaneous injection once weekly. Atacicept blocks both B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), thereby inhibiting the stimulation of B cells and plasma cells that produce autoantibodies contributing to autoimmune diseases such as IgA nephropathy (IgAN) and lupus nephritis.

One of the company's significant achievements is the development of atacicept, which has shown promising results in clinical trials. The Phase 2b ORIGIN clinical trial demonstrated atacicept's potential to modify disease progression in IgAN patients, with data showing consistent and sustained reductions in Gd-IgA1, hematuria, and UPCR, along with stable eGFR over 72 weeks. The ongoing pivotal Phase 3 ORIGIN 3 trial aims to further evaluate atacicept's efficacy and safety in a larger cohort of IgAN patients.

Additionally, Vera is advancing MAU868, a monoclonal antibody designed to neutralize BK virus (BKV) infections, which are particularly problematic in kidney transplant patients. Vera retains global developmental and commercial rights to both atacicept and MAU868, positioning the company well in the biopharmaceutical market.

Financially, Vera reported a net loss of $28.4 million for the quarter ended March 31, 2024, with sufficient cash reserves to fund operations through the potential approval and U.S. launch of atacicept. The company has also announced various strategic partnerships and funding rounds to support its ambitious research and development goals.

Recently, Vera Therapeutics received FDA Breakthrough Therapy Designation for atacicept in IgAN, indicating the drug's potential to substantially improve kidney function compared to existing therapies. This designation expedites the development and review process, bringing hope to patients suffering from this debilitating disease.

For more information about Vera Therapeutics and its clinical trials, please visit the company's website at www.veratx.com.

Rhea-AI Summary

Vera Therapeutics, Inc. announced positive interim data from its Phase 2b ORIGIN clinical trial of atacicept in IgA Nephropathy (IgAN), revealing a 41% mean reduction in proteinuria for the 150mg dose group at 24 weeks. The company plans to start a Phase 3 clinical trial in Q2 2023 and expects to release 36-week data from ORIGIN then. Vera reported a net loss of $89.1 million for 2022, increasing from $32.6 million in the previous year. Despite this, it has a strong balance sheet with approximately $188 million from recent follow-on offerings, supporting operations through early 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
-
Rhea-AI Summary

Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company, will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference in Boston from March 6 – 8, 2023. The chat is scheduled for March 6 at 2:10 PM ET and will be available via webcast. Additionally, the management team will hold one-on-one investor meetings at the event. Vera focuses on developing transformative treatments for serious immunological diseases, with its lead product candidate, atacicept, targeting conditions like IgA nephropathy and lupus nephritis. A replay of the event will be accessible for 90 days on their website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
conferences
-
Rhea-AI Summary

On February 6, 2023, Vera Therapeutics (NasdaqGM: VERA) announced the successful closing of its underwritten public offering of 16,428,572 shares of Class A common stock at a price of $7.00 per share. This transaction, which includes the full exercise of the underwriters' option to purchase an additional 2,142,857 shares, is expected to generate gross proceeds of approximately $115 million before expenses. J.P. Morgan, Cowen, and Evercore ISI led the offering, which was conducted under an effective shelf registration statement. Vera focuses on transformative treatments for serious immunological diseases, including its lead product candidate, atacicept.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.15%
Tags
Rhea-AI Summary

Vera Therapeutics, Inc. (NasdaqGM: VERA) has priced its public offering of 14,285,715 shares of Class A common stock at $7.00 per share, aiming to raise gross proceeds of $100 million. A 30-day option for underwriters to purchase an additional 2,142,857 shares is included. The offering is set to close on February 6, 2023, pending customary conditions. The initiative is supported by a shelf registration statement declared effective on June 13, 2022. Vera focuses on transformative treatments for serious immunological diseases, with candidates like atacicept and MAU868 in its pipeline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.72%
Tags
-
Rhea-AI Summary

Vera Therapeutics, a late-stage biotechnology company, has announced a public offering of $75 million shares of its Class A common stock, aimed at developing treatments for serious immunological diseases. The offering is subject to market conditions, with underwriters being granted a 30-day option to purchase an additional 15% of the shares. J.P. Morgan, Cowen, and Evercore ISI are the joint book-running managers. Vera's lead candidate, atacicept, targets autoimmune diseases including IgA nephropathy and lupus nephritis, while MAU868 addresses BK Virus infections. The offering will be conducted under a shelf registration statement and the company holds full rights to its drug candidates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.72%
Tags
-
Rhea-AI Summary

Vera Therapeutics focuses on advancing atacicept, a promising treatment for IgA nephropathy, into a pivotal Phase 3 trial in 1H 2023. Recent results from the Phase 2b ORIGIN trial showed a 47% mean reduction in proteinuria at Week 36 for the 150 mg atacicept group versus baseline, indicating significant efficacy. The drug was well-tolerated, with a 1% discontinuation rate due to adverse events. Vera plans to extend its cash runway to Q4 2024 while prioritizing resources for the upcoming pivotal trial. Full data will be showcased at medical congresses, with a focus on further informing the Phase 3 trial design.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.06%
Tags
Rhea-AI Summary

Innocoll Holdings Ltd. has appointed Kimball Hall as President and Chief Executive Officer, bringing over 30 years of experience in commercial operations. Hall will also lead Innocoll's subsidiaries, Syntacoll GmbH and Innocoll Biotherapeutics Inc., focusing on expanding their services and product offerings. Previously, Hall served as President and COO at Abzena, overseeing multiple manufacturing sites. Gurnet Point Capital, Innocoll's parent company, expressed confidence in Hall’s ability to drive growth, particularly in non-opioid pain management products like Xaracoll® and Posimir®.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
management
-
Rhea-AI Summary

Vera Therapeutics (Nasdaq: VERA) has announced an upcoming virtual key opinion leader (KOL) event featuring Dr. Jonathan Barratt from the University of Leicester. The event will provide updates on atacicept’s ORIGIN Phase 2b data focused on IgA nephropathy (IgAN). Atacicept is a dual inhibitor aimed at treating IgAN, a serious autoimmune kidney disease. The ORIGIN trial involves 116 patients testing the efficacy and safety of atacicept against a placebo. Primary endpoints include changes in proteinuria at 24 weeks. The company aims to address the high unmet medical need in IgAN treatment, leveraging data from this and future trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
none
-
Rhea-AI Summary

Vera Therapeutics announced that the Phase 2b ORIGIN clinical trial of atacicept in patients with immunoglobulin A nephropathy (IgAN) achieved its primary endpoint, showing a 31% mean reduction in proteinuria at 24 weeks, with statistical significance (p=0.037). The 150 mg dose group exhibited a 33% mean reduction (p=0.047), indicating potential for significant therapeutic benefit. The safety profile of atacicept was comparable to placebo, with plans to progress to a pivotal Phase 3 trial in the first half of 2023. An investor call is scheduled for January 4, 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-64.7%
Tags
Rhea-AI Summary

Vera Therapeutics, a late-stage biotechnology firm, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco from January 9-12, 2023. The presentation is scheduled for January 10th at 1:30 PM PT. Vera focuses on treatments for immunological diseases, with its leading candidate, atacicept, targeting autoimmune conditions like IgA nephropathy and lupus nephritis. Investors can access the webcast here, with a replay available for 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.44%
Tags
conferences

FAQ

What is the current stock price of Vera Therapeutics (VERA)?

The current stock price of Vera Therapeutics (VERA) is $47.03 as of November 21, 2024.

What is the market cap of Vera Therapeutics (VERA)?

The market cap of Vera Therapeutics (VERA) is approximately 3.0B.

What is Vera Therapeutics?

Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases.

What is atacicept?

Atacicept is a fusion protein developed by Vera Therapeutics for the treatment of autoimmune diseases, administered as a subcutaneous injection once weekly.

What is the ORIGIN clinical trial?

The ORIGIN clinical trial is a series of studies evaluating the safety and efficacy of atacicept in patients with IgA nephropathy (IgAN).

What is IgA nephropathy (IgAN)?

IgAN, also known as Berger’s disease, is a serious autoimmune disease of the kidney characterized by the production of immunogenic Gd-IgA1 and progressive kidney damage.

What is MAU868?

MAU868 is a monoclonal antibody developed by Vera Therapeutics to neutralize BK virus (BKV) infections, particularly in kidney transplant patients.

What recent achievements has Vera Therapeutics reported?

Vera recently announced positive 72-week data from its Phase 2b ORIGIN trial of atacicept in IgAN and received FDA Breakthrough Therapy Designation for atacicept.

How is atacicept administered?

Atacicept is administered as a subcutaneous injection once weekly.

What are the financial highlights of Vera Therapeutics?

For the quarter ended March 31, 2024, Vera reported a net loss of $28.4 million, with cash reserves to fund operations through the approval and U.S. launch of atacicept.

Who are Vera’s strategic partners?

Vera has various strategic partnerships and funding rounds to support its research and development, including J.P. Morgan, TD Cowen, and Evercore ISI.

Where can I find more information about Vera Therapeutics?

For more information, please visit the company's website at www.veratx.com.

Vera Therapeutics, Inc.

Nasdaq:VERA

VERA Rankings

VERA Stock Data

2.97B
58.33M
6.74%
94.71%
10.31%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BRISBANE